Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14988285 | 0.82 | ALOX5AP (0.43) | NPC1RAB9AGPR84KMT2APOLB | |
| SCHEMBL20745885 | 0.81 | KDM4E (0.44) | GABRA5GPR84ALDH1A1LMNA | |
| SCHEMBL5857777 | 0.81 | GABRA5 (0.37) | GABRA5NPC1RAB9ANPSR1SMN1; SMN2 | |
| SCHEMBL1928209 | 0.78 | RAB9A (0.54) | NPC1RAB9AKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL840756 | 0.78 | HCAR3 (0.60) | NPC1RAB9AKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL14988307 | 0.77 | MAPT (0.47) | GABRA5GPR84KMT2APOLBNPSR1 | |
| SCHEMBL1929309 | 0.76 | KDM1A (0.45) | GABRA5NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL20775355 | 0.76 | KDM1A (0.45) | GABRA5NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL1390734 | 0.76 | KDM1A (0.47) | GABRA5NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL20775288 | 0.76 | KDM1A (0.42) | GABRA5FEN1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152234-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2011-06-23 | — | — | US | disclosed |
| US-7956084-B2 | Phenyl thiophene carboxamide compounds as inhibitors of the enzyme IKK-2 | ASTRAZENECA AB (SE) | 2011-06-07 | — | — | US | disclosed |
| EP-1421074-B1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2010-09-29 | — | — | EP | disclosed |
| US-20070015819-A1 | Novel compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2007-01-18 | — | — | US | disclosed |
| US-7125896-B2 | Thiophene carboxamide compounds as inhibitors of enzyme IKK-2 | ASTRAZENECA AB (SE) | 2006-10-24 | — | — | US | disclosed |
| US-20040242573-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2004-12-02 | — | — | US | disclosed |
| EP-1421074-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2004-05-26 | — | — | EP | disclosed |
| WO-2003010158-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015819-A1 | Novel compounds | CNR1, ABCG2, CNR2 | GABRA5 1502/4885NPC1 758/4885RAB9A 1662/4885 |
| US-20040242573-A1 | Novel compounds | SULT1E1, TPMT, UGT1A1 | GABRA5 2376/4885NPC1 424/4885RAB9A 319/4885 |
| US-20110152234-A1 | Novel Compounds | CNR1, ABCG2, CNR2 | GABRA5 1502/4885NPC1 758/4885RAB9A 1662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.